Journal
LANCET
Volume 361, Issue 9360, Pages 836-838Publisher
LANCET LTD
DOI: 10.1016/S0140-6736(03)12681-5
Keywords
-
Categories
Ask authors/readers for more resources
Despite advances In the molecular pathogenesis of giloblastoma multiforme, no reliable prognostic markers have been Identified. We analysed telomerase activity and telomere lengths In giloblastoma multiformes from 77 patients. 19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype. Median survival for patients with this phenotype was 542 days (95% CI 114-970) compared with 247 days (224-270) for glioblastoma multiformes with normal telomeres (p=0.0003). Cox's regression analysis showed that this association is independent of age. In patients with non-ALT tumours, telomerase activity did not affect survival (median 287 [199-375] vs 236 [230-242] days, p=0.275). We conclude that ALT Is a prognostic Indicator for patients with glioblastoma multiforme.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available